Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CERo Therapeutics Holdings ( (CERO) ) has provided an announcement.
On May 29, 2025, CERo Therapeutics Holdings held its Annual Meeting of Stockholders, where several key proposals were approved, including an amendment to increase the number of shares available under the 2024 Equity Incentive Plan by 2,000,000 shares. The meeting also saw the approval of a Reverse Stock Split at a ratio of one-for-twenty, which is expected to impact the company’s stock trading post-split. These decisions are poised to influence the company’s operational strategy and market positioning, with implications for stakeholders as the company aligns with Nasdaq requirements.
The most recent analyst rating on (CERO) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings operates in the biotechnology industry, focusing on developing innovative therapeutic solutions. The company primarily offers equity incentive plans and engages in stock-related activities to enhance its market presence.
Average Trading Volume: 1,914,488
Technical Sentiment Signal: Sell
Current Market Cap: $4.02M
For an in-depth examination of CERO stock, go to TipRanks’ Stock Analysis page.